Drugs / Nω-hydroxy-nor-arginine
Nω-hydroxy-nor-arginine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05536934 | Dec 2016 → Sep 2021 | obesity disorder | Karolinska Institutet | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nω-hydroxy-nor-arginine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05536934 ↗ |
| Known as | N-omega-hydroxy-nor-l-arginine | “arginase inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA)” NCT05536934 ↗ |
| Known as | nor-NOHA | “arginase inhibitor N-omega-hydroxy-nor-l-arginine (nor-NOHA)” NCT05536934 ↗ |
| Action | Inhibit | “arginase inhibitor” NCT05536934 ↗ |
| Route | Other | “intra-arterial infusion” NCT05536934 ↗ |